EcoDrugPlus

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSRFEG00010019439
Gene Symbol: PPARD
1 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSRFEG00010018692
Gene Symbol: PPARG
1 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSRFEG00010021761
Gene Symbol: PIK3CA
1 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSRFEG00010012826
Gene Symbol: PIK3CB
1 Cross references
215 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSRFEG00010013099
Gene Symbol: PIK3CD
1 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSRFEG00010017728
Gene Symbol: PIK3CG
1 Cross references
213 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSRFEG00010019378
Gene Symbol: PDE3A
1 Cross references
272 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSRFEG00010021438
Gene Symbol: PDE3B
1 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSRFEG00010014770
Gene Symbol: PDE4A
1 Cross references
275 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSRFEG00010004177
Gene Symbol: PDE4B
1 Cross references
292 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSRFEG00010019392
Gene Symbol: PDE4C
1 Cross references
269 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSRFEG00010015613
Gene Symbol: PDE4D
1 Cross references
244 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).